Forte Biosciences, Inc. Announces 2023 EPS $(1.00) Vs $(0.80) YoY
Forte Biosciences, Inc. Announces 2023 EPS $(1.00) Vs $(0.80) YoY
Net losses per share were ($1.00) and ($0.80) for the years ended December 31, 2023 and 2022, respectively.2023 Operating Results
2023 年经营业绩
Research and development expenses were $21.9 million for the year ended December 31, 2023, compared to $5.6 million during the same period in 2022. The increase of $16.3 million was primarily due to a net increase of approximately $9.9 million in manufacturing expense, a net increase of approximately $6.0 million in preclinical and clinical expenses as our FB-102 program entered the clinic, and a net increase in payroll and related expenses of approximately $0.4 million primarily due to an increase in headcount.
截至2023年12月31日的财年，研发费用为2190万美元，而2022年同期为560万美元。增加1,630万美元的主要原因是制造费用净增加约990万美元，随着我们的 FB-102 计划进入临床，临床前和临床费用净增加约600万美元，工资和相关费用净增加约40万美元，这主要是由于员工人数的增加。
General and administrative expenses were $10.6 million for the year ended December 31, 2023, compared to $8.3 million for the same period in 2022. The increase of $2.3 million was primarily due to an increase in professional and legal expenses of $2.6 million, an increase in other expenses of $0.4 million, including rent and personnel expenses, partially offset by a reduction in stock-based compensation expense of $0.7 million.
截至2023年12月31日的财年，一般和管理费用为1,060万美元，而2022年同期为830万美元。增加230万美元的主要原因是专业和法律费用增加了260万美元，包括租金和人事支出在内的其他支出增加了40万美元，但股票薪酬支出减少了70万美元，部分抵消了这一增加。
Net losses per share were ($1.00) and ($0.80) for the years ended December 31, 2023 and 2022, respectively.
截至2023年12月31日和2022年12月31日止年度的每股净亏损分别为（1.00美元）和（0.80美元）。
Forte ended 2023 with approximately $37.1 million in cash and cash equivalents. Forte had approximately 36.3 million shares of common stock outstanding as of December 31, 2023.
截至2023年，Forte拥有约3710万美元的现金和现金等价物。截至2023年12月31日，Forte的已发行普通股约为3630万股。
